BidaskClub downgraded shares of China Biologic Products, Inc. (NASDAQ:CBPO) from a hold rating to a sell rating in a research report released on Sunday morning.

Several other equities research analysts have also weighed in on the company. Zacks Investment Research raised China Biologic Products from a sell rating to a hold rating in a research note on Tuesday, July 4th. Jefferies Group LLC reissued a buy rating and set a $140.00 price objective on shares of China Biologic Products in a research note on Monday, June 12th. Finally, Goldman Sachs Group, Inc. (The) assumed coverage on China Biologic Products in a research note on Tuesday, May 30th. They set a neutral rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $132.00.

Shares of China Biologic Products (NASDAQ CBPO) traded down 0.89% during mid-day trading on Friday, hitting $101.86. The stock had a trading volume of 173,996 shares. The firm has a market cap of $2.77 billion, a P/E ratio of 26.38 and a beta of 1.74. The company has a 50 day moving average price of $111.44 and a 200 day moving average price of $109.44. China Biologic Products has a 12-month low of $96.99 and a 12-month high of $137.38.

TRADEMARK VIOLATION NOTICE: “China Biologic Products, Inc. (CBPO) Downgraded by BidaskClub to Sell” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/07/16/china-biologic-products-inc-cbpo-downgraded-by-bidaskclub-to-sell.html.

In other news, insider Zhijing Cbpo Liu sold 7,500 shares of the firm’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $116.49, for a total transaction of $873,675.00. Following the completion of the sale, the insider now directly owns 10,969 shares of the company’s stock, valued at approximately $1,277,778.81. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 2.73% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. UBS Asset Management Americas Inc. boosted its stake in shares of China Biologic Products by 9.3% in the first quarter. UBS Asset Management Americas Inc. now owns 198,220 shares of the biopharmaceutical company’s stock valued at $19,848,000 after buying an additional 16,933 shares during the period. Pictet Asset Management Ltd. acquired a new stake in shares of China Biologic Products during the first quarter valued at approximately $1,762,000. Bank of New York Mellon Corp boosted its stake in shares of China Biologic Products by 5.9% in the first quarter. Bank of New York Mellon Corp now owns 563,527 shares of the biopharmaceutical company’s stock valued at $56,426,000 after buying an additional 31,297 shares during the period. Henderson Group PLC boosted its stake in shares of China Biologic Products by 9.3% in the first quarter. Henderson Group PLC now owns 188,585 shares of the biopharmaceutical company’s stock valued at $18,877,000 after buying an additional 16,017 shares during the period. Finally, First Trust Advisors LP boosted its stake in shares of China Biologic Products by 35.9% in the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock valued at $1,158,000 after buying an additional 3,053 shares during the period. 74.28% of the stock is owned by institutional investors and hedge funds.

China Biologic Products Company Profile

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.

Receive News & Stock Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related stocks with our FREE daily email newsletter.